Open Source Securities released a research report on April 19 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) rapid growth in 2023 performance, outstanding market advantages for a full range of rehabilitation solutions, maintaining “buying” reviews; 2) the rehabilitation circuit is destined for long-term stable development in the context of accelerated aging, and rehabilitation leaders will benefit more and more; 3) 2024Q1 revenue achieved steady growth under a high base, laying a solid foundation for achieving annual revenue goals. (Mainichi Keizai Shimbun)
开源证券4月19日发布研报称，给予翔宇医疗（688626.SH）买入评级。评级理由主要包括：1）2023年业绩快速增长，全系列康复解决方案市场优势突出，维持“买入”评；2）康复赛道在老龄化加速背景下注定长期稳定发展，康复龙头愈加受益；3）2024Q1收入在高基数下实现稳健增长，为全年收入目标达成奠定坚实基础。（每日经济新闻）
Open Source Securities released a research report on April 19 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) rapid growth in 2023 performance, outstanding market advantages for a full ran
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated